Denali Therapeutics Inc
NASDAQ:DNLI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.96
31.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Denali Therapeutics Inc
Denali Therapeutics Inc
Cash from Financing Activities
Denali Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Cash from Financing Activities
$493.2m
|
CAGR 3-Years
175%
|
CAGR 5-Years
142%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$2.8B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Denali Therapeutics Inc
Glance View
In the heart of the biotech innovation hub that is California, Denali Therapeutics Inc. emerges as a promising beacon in the landscape of neurodegenerative disease treatment. Established by a team of pioneers in 2015, the company aims to combat the pressing challenge of diseases like Alzheimer's, Parkinson’s, and ALS. At the core of Denali’s mission is a sophisticated approach that intersects genetics, engineering, and clinical research. This biotech firm is not just about dreaming big; it operationalizes its vision through a science-driven methodology. Denali leverages its proprietary "Transport Vehicle" technology to enhance the delivery of therapeutic antibodies across the blood-brain barrier—a critical hurdle in treating neurological disorders. By addressing genetic underpinnings and homeostasis dysfunctions, Denali positions itself as a driver of transformative healthcare solutions. Denali's business model revolves around the development and commercialization of novel therapeutics. With a focus on high unmet needs, the company aligns its research objectives with revenue generation through strategic collaborations and partnerships. These alliances bolster Denali’s financial foundation, offering resources and expertise to hasten drug development and commercialization. Denali engages in research and licensing agreements that bring in upfront payments, milestone rewards, and future royalties. This approach not only diversifies its income streams but also mitigates risks associated with drug development intricacies. As Denali nurtures its pipeline, revenue opportunities expand, resting on the successful translation of groundbreaking science into tangible, market-ready solutions that offer hope to millions grappling with debilitating neurological conditions.
See Also
What is Denali Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
493.2m
USD
Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's Cash from Financing Activities amounts to 493.2m USD.
What is Denali Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
142%
Over the last year, the Cash from Financing Activities growth was 58%. The average annual Cash from Financing Activities growth rates for Denali Therapeutics Inc have been 175% over the past three years , 142% over the past five years .
You don't have any saved screeners yet
